Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.
Integration of exogenous DNA into modified vaccinia Ankara (MVA) is often accomplished using mapped deletion sites in the viral genome. Since MVA has a large capacity (> or =30kb) for foreign gene inserts and a limited number of unique integration sites, development of additional integration sites is needed to take full advantage of the extraordinary capacity for foreign gene insertion. In this report, we evaluate an alternative insertion site known as intergenic region 3 (IGR3). Recombinant MVA carrying the cytomegalovirus pp65 gene in IGR3 (rMVA-pp65-IGR3) demonstrated expression and genetic stability of the insert gene upon passage. Immunization of transgenic HLA-A2 mice with rMVA-pp65-IGR3 induced robust antigen-specific immune responses. Moreover, rMVA-pp65-IGR3-infected human EBV-transformed B cell lines were able to stimulate high levels of pp65-specific memory T cell responses in human PBMCs. These data support the usage of IGR3 for the development of highly immunogenic rMVA vaccines for clinical or veterinary use.
Manuel
Edwin R
ER
Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Wang
Zhongde
Z
Li
Zhongqi
Z
La Rosa
Corinna
C
Zhou
Wendi
W
Diamond
Don J
DJ
D000818:Animals; D000941:Antigens / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D022482:Cytomegalovirus Vaccines / Q000235:genetics / Q000276:immunology; D021901:DNA, Intergenic; D015870:Gene Expression; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics*
D000941:Antigens; D022482:Cytomegalovirus Vaccines; D021901:DNA, Intergenic; D014614:Vaccines, Synthetic
J Gen Virol. 2005 Nov;86(Pt 11):2925-2936
16227213
Cancer Res. 2003 Nov 15;63(22):7942-9
14633725
Virology. 2008 Aug 1;377(2):379-90
18538366
Vaccine. 2006 May 22;24(21):4618-21
16157428
Cancer Immunol Immunother. 2000 Jun;49(3):123-32
10881691
Dev Biol Stand. 1978;41:225-34
223909
Curr Gene Ther. 2008 Apr;8(2):97-120
18393831
Hepatology. 2001 Aug;34(2):372-6
11481622
J Gen Virol. 1991 May;72 ( Pt 5):1031-8
2033387
Mol Cell Biol. 1985 Dec;5(12):3403-9
3939316
Nat Med. 2007 Jan;13(1):100-6
17187074
J Exp Med. 1997 Jun 16;185(12):2043-51
9182675
Med Microbiol Immunol. 2008 Jun;197(2):117-23
18196272
Vaccine. 2007 Jan 22;25(6):1132-41
17049414
Vaccine. 2010 Feb 10;28(6):1547-57
19969118
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8
8876137
Virology. 2007 Sep 15;366(1):84-97
17499326
J Med Virol. 1994 May;43(1):103-10
8083644
Curr Opin Biotechnol. 2004 Dec;15(6):506-12
15560976
Virology. 2008 Mar 15;372(2):260-72
18048074
J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
9472619
Exp Hematol. 2006 Apr;34(4):497-507
16569596
Blood. 2004 Aug 1;104(3):847-56
15090456
Gene. 1996 Jun 26;172(2):233-7
8682309
Vaccine. 2009 Sep 25;27(42):5885-95
19654066
Blood. 1997 Sep 1;90(5):1751-67
9292508
Immunol Lett. 2008 Oct 30;120(1-2):108-16
18706443
Vaccine. 2007 Apr 12;25(15):2863-85
17113200
J Virol. 2004 Apr;78(8):3965-76
15047812
J Clin Virol. 2006 Mar;35(3):324-31
16388983
J Virol. 2004 Apr;78(7):3333-42
15016855
Nat Biotechnol. 2002 Jan;20(1):87-90
11753368
J Immunol. 1991 Sep 1;147(5):1512-21
1715361
Cancer Immunol Immunother. 2005 May;54(5):453-67
15627214
J Immunother. 2009 Sep;32(7):765-72
19561532
J Virol. 1996 Nov;70(11):7569-79
8892876
AIDS Res Hum Retroviruses. 2008 Feb;24(2):195-206
18240957
J Virol. 1994 Jan;68(1):130-47
8254722
Acta Virol. 2001;45(4):243-7
11885931
J Virol. 1998 Apr;72(4):2917-26
9525612
J Virol. 2000 Jan;74(2):923-33
10623755
J Virol. 2009 Jul;83(14):7176-84
19420086